参考文献/References:
[1].Li H,Liu Y,Huang H,et al. Activation of β3-adrenergic receptor inhibits ventricular arrhythmia in heart failure through calcium handling[J]. Tohoku J Exp Med,2010,222(3):167-174.
[2].李诗洋,席小青,柳达,等. β1、β3 肾上腺素受体自身抗体与老年慢性心力衰竭恶性心律失常的相关性[J]. 世界最新医学信息文摘,2018,18(26):12-13.
[3].Schena G,Caplan MJ. Everything You Always Wanted to Know about β3-AR * (* But Were Afraid to Ask)[J].Cells,2019,8(4):357-380.
[4].Dessy C,Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues:emerging concepts and therapeutic perspectives[J]. ?Adv Pharmacol,2010,59(1):135-163.
[5]. Michel LYM,Balligand JL. New and emerging therapies and targets:beta-3 agonists[J]. Handb Exp Pharmacol,2017,243:205-223.
[6]. Cannavo A,Koch WJ. Targeting β3-adrenergic receptors in the heart:selective agonism and β-blockade[J]. J Cardiovasc Pharmacol,2017,69(2):71-78.
[7]. Rozec B,Gauthier C. Beta3-adrenoceptors in the cardiovascular system:putative roles in human pathologies[J]. Pharmacol Ther,2006,111(3):652-673.
[8]. Balligand JL. Cardiac salvage by tweaking with beta-3-adrenergic receptors[J]. Cardiovasc Res,2016,111(2):128-133.
[9]. Cannavo A,Koch WJ. Targeting β3-adrenergic receptors in the heart:selective agonism and β-blockade[J]. J Cardiovasc Pharmacol,2017,69(2):71-78.
[10].Yang LK,Tao YX. Physiology and pathophysiology of the β3-adrenergic receptor[J]. Prog Mol Biol Transl Sci,2019,161:91-112.
[11].Dessy C,Moniotte S,Ghisdal P,et al. Endothelial beta3 -adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization[J]. Circulation,2004,110(8):948-954.
[12].Moniotte S,Kobzik L,Feron O,et al. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium[J]. Circulation,2001,103 (12):1649-1655.
[13].李为民,孔一慧,田颖,等. β3受体激动剂对心力衰竭大鼠β1、β2、β3肾上腺素能受体mRNA表达水平影响的实验研究[J]. 中华心血管病杂志,2003,31(1):11-16.
[14].Li B,Zhao Q,Wang LX,et al. Effect of β3-adrenergic receptor on atrial L-type Ca(2+) current in rats with chronic heart failure[J]. Heart Lung Circ,2014,23(4):369-377.
[15].林继红,甘润韬,李为民,等. β3肾上腺素能受体阻滞剂SR59230A对心力衰竭大鼠心功能及β3肾上腺素能受体表达的影响[J]. 中国药房,2008,19(16):1214-1216.
[16].Wang B,Xu M,Li W,et al. Aerobic exercise protects against pressure overload-induced cardiac dysfunction and hypertrophy via β3-AR-nNOS-NO activation[J]. PLoS One,2017,12(6):e0179648.
[17].Trappanese DM,Liu Y,McCormick RC,et al. Chronic β 1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload:new insight into mechanisms of cardiac benefit with selective β 1-blocker therapy[J]. Basic Res Cardiol,2015,110(1):456.
[18].Cannavo A,Rengo G,Liccardo D,et al. β1-blockade prevents post-ischemic myocardial decompensation via β3AR-dependent protective sphingosine-1 phosphate signaling[J]. J Am Coll Cardiol,2017,70(2):182-192.
[19]. Bundgaard H,Axelsson A,Hartvig Thomsen J,et al. The-first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure:the BEAT-HF trial[J]. Eur J Heart Fail,2017,19(4):566-575.
[20]. 李兴怡,刘佳,富路. 心力衰竭合并室性心律失常的研究及治疗进展[J]. 心血管病学进展,2019,40(3):400-403.
[21].邓义军,伍卫,黄至斌,等. 心力衰竭大鼠β3-肾上腺素能受体兴奋对室颤阈值和心室有效不应期的影响[J]. 中国病理生理杂志,2007,23(5):848-852.
[22].Zhou S,Tan AY,Paz O,et al. Antiarrhythmic effects of β3-adrenergic receptor stimulation in a canine model of ventricular tachycardia[J]. Heart Rhythm,2008,5(2):289-297.
[23].李海涛,吴明,马建林,等. 激活β3肾上腺素能受体对心衰家兔室性心律失常及心率变异性、心率震荡的影响[J]. 海南医学,2014,25(16):2344-2346.
[24].Ma Y,Bai F,Qin F,et al． Catheter ablation for treatment of patients with atrial fibrillation and heart failure:a meta-analysis of randomized controlled trials [J]. BMC Cardiovasc Disord,2018,18(1):165-172．
[25].Nattel S,Harada M. Atrial remodeling and atrial fibrillation:recent advances and translational perspectives[J]. J Am Coll Cardiol,2014,63(22):2335-2345.
[26].Cha TJ,Ehrlich JR,Zhang L,et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure[J]. Circulation,2004,109(3):412-418.
[27].Zhao Q,Zeng F,Liu JB,et al. Upregulation of β3-adrenergic receptor expression in the atrium of rats with chronic heart failure[J]. J Cardiovasc Pharmacol Ther,2013,18(2):133-137．
[28].Wang X,Wang R,Liu G,et al. The β3 adrenergic receptor agonist BRL37344 exacerbates atrial structural remodeling through iNOS uncoupling in canine models of atrial fibrillation[J]. Cell Physiol Biochem,2016,38(2):514-530.
[29].van den Berg NWE,Kawasaki M,Berger WR,et al. MicroRNAs in atrial fibrillation:from expression signatures to functional implications[J]. Cardiovasc Drugs Ther,2017,31(3):345-365．
[30]. 赵强,邹月柳,邹筱冬,等. β3肾上腺素能受体通过微小RNA对慢性心力衰竭大鼠左心房肌L型钙离子通道的调控[J]. 中华老年心脑血管病杂志,2019,21(1):67-71.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(1):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(1):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(1):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(1):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(1):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]